JAMA Internal Medicine
EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, FEBRUARY 3, 2020
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2019.7108?guestAccessKey=89c288fa-4300-46a9-b9a9-0d3bbefb12fc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020320
What The Study Did: Researchers calculated the average cost of recommended initial HIV antiretroviral therapy (ART) regimens in the U.S. from 2012 to 2018 and analyzed how this cost has changed over the years. High ART costs are one of the factors that can lead to poor HIV treatment and outcomes in the U.S.
Authors: Rochelle P. Walensky, M.D., M.P.H., of Massachusetts General Hospital in Boston, is the corresponding author.
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.